Wen Su1, Rong Cao2, Yong Cheng He2, You Fei Guan3, Xiong Zhong Ruan4. 1. AstraZeneca - Shenzhen University Joint Institute of Nephrology, Center for Nephrology and Urology, Department of Physiology, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China. 2. Department of Nephrology, The First Affiliated Hospital of Shenzhen University, Shenzhen, China. 3. Advanced Institute for Medical Sciences, Dalian Medical University, Dalian, China. 4. John Moorhead Research Laboratory, Centre for Nephrology, University College London Medical School, Royal Free Campus, London, UK.
Abstract
BACKGROUND: Diabetic kidney disease (DKD) is defined by the functional, structural, and clinical abnormalities of the kidney that are caused by diabetes. SUMMARY: One-third of both type 1 diabetes and type 2 diabetes patients suffer from DKD, which is the leading cause of end-stage renal disease, and is also associated with cardiovascular disease and high public health care costs. Serum glucose level and lipid level are key factors in the pathogenesis of DKD and are modifiable. The goal of this review is to provide an update on the roles of glucose and lipid metabolism in DKD and their crosstalk at the molecular level. We will further discuss the recent advances regarding metabolic nuclear receptors in glucose-lipid crosstalk, which may provide new potential therapeutic targets for DKD. KEY MESSAGE: AMPK, SREBP-1, and some metabolic hormone receptors including liver X receptors, farnesoid X receptors, and peroxisome proliferator-activated receptors mediate the crosstalk of hyperglycemia and dyslipidemia in diabetic kidney disease and might be potential treatment candidates.
BACKGROUND: Diabetic kidney disease (DKD) is defined by the functional, structural, and clinical abnormalities of the kidney that are caused by diabetes. SUMMARY: One-third of both type 1 diabetes and type 2 diabetes patients suffer from DKD, which is the leading cause of end-stage renal disease, and is also associated with cardiovascular disease and high public health care costs. Serum glucose level and lipid level are key factors in the pathogenesis of DKD and are modifiable. The goal of this review is to provide an update on the roles of glucose and lipid metabolism in DKD and their crosstalk at the molecular level. We will further discuss the recent advances regarding metabolic nuclear receptors in glucose-lipid crosstalk, which may provide new potential therapeutic targets for DKD. KEY MESSAGE: AMPK, SREBP-1, and some metabolic hormone receptors including liver X receptors, farnesoid X receptors, and peroxisome proliferator-activated receptors mediate the crosstalk of hyperglycemia and dyslipidemia in diabetic kidney disease and might be potential treatment candidates.
Authors: James M McKenney; Michael J Koren; Dean J Kereiakes; Corinne Hanotin; Anne-Catherine Ferrand; Evan A Stein Journal: J Am Coll Cardiol Date: 2012-03-28 Impact factor: 24.094
Authors: R S Hundal; M Krssak; S Dufour; D Laurent; V Lebon; V Chandramouli; S E Inzucchi; W C Schumann; K F Petersen; B R Landau; G I Shulman Journal: Diabetes Date: 2000-12 Impact factor: 9.461
Authors: Evan A Stein; Dan Gipe; Jean Bergeron; Daniel Gaudet; Robert Weiss; Robert Dufour; Richard Wu; Robert Pordy Journal: Lancet Date: 2012-05-26 Impact factor: 79.321
Authors: A H Hasty; H Shimano; N Yahagi; M Amemiya-Kudo; S Perrey; T Yoshikawa; J Osuga; H Okazaki; Y Tamura; Y Iizuka; F Shionoiri; K Ohashi; K Harada; T Gotoda; R Nagai; S Ishibashi; N Yamada Journal: J Biol Chem Date: 2000-10-06 Impact factor: 5.157
Authors: Joseph T Rodgers; Carlos Lerin; Wilhelm Haas; Steven P Gygi; Bruce M Spiegelman; Pere Puigserver Journal: Nature Date: 2005-03-03 Impact factor: 49.962
Authors: Samuel Bernardo-Bermejo; Elena Sánchez-López; María Castro-Puyana; Selma Benito-Martínez; Francisco Javier Lucio-Cazaña; María Luisa Marina Journal: Molecules Date: 2020-01-24 Impact factor: 4.411